306 related articles for article (PubMed ID: 6272964)
1. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis.
Klein E; Ernberg I; Masucci MG; Szigeti R; Wu YT; Masucci G; Svedmyr E
Cancer Res; 1981 Nov; 41(11 Pt 1):4210-5. PubMed ID: 6272964
[TBL] [Abstract][Full Text] [Related]
2. In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.
Strang G; Rickinson AB
Immunology; 1987 Dec; 62(4):647-54. PubMed ID: 2828228
[TBL] [Abstract][Full Text] [Related]
3. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.
Thorley-Lawson DA
J Immunol; 1980 Feb; 124(2):745-51. PubMed ID: 6243331
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
5. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
6. Suppressor T cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis.
Wang F; Blaese RM; Zoon KC; Tosato G
J Clin Invest; 1987 Jan; 79(1):7-14. PubMed ID: 3025263
[TBL] [Abstract][Full Text] [Related]
7. T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals.
Tosato G; Magrath IT; Blaese RM
J Immunol; 1982 Feb; 128(2):575-9. PubMed ID: 6274959
[TBL] [Abstract][Full Text] [Related]
8. Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis).
Tosato G; Straus S; Henle W; Pike SE; Blaese RM
J Immunol; 1985 May; 134(5):3082-8. PubMed ID: 2984282
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis.
Hudnall SD; Patel J; Schwab H; Martinez J
Cytometry B Clin Cytom; 2003 Sep; 55(1):22-8. PubMed ID: 12949956
[TBL] [Abstract][Full Text] [Related]
10. Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis.
Borysiewicz LK; Haworth SJ; Cohen J; Mundin J; Rickinson A; Sissons JG
Q J Med; 1986 Feb; 58(226):111-21. PubMed ID: 3012622
[TBL] [Abstract][Full Text] [Related]
11. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
Yanagisawa M; Kato M; Ikeno K; Kobayashi T; Miyagawa Y; Komiyama A; Akabane T
Clin Exp Immunol; 1987 May; 68(2):251-8. PubMed ID: 2820633
[TBL] [Abstract][Full Text] [Related]
12. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis.
Al Tabaa Y; Tuaillon E; Jeziorski E; Ouedraogo DE; Bolloré K; Rubbo PA; Foulongne V; Rodière M; Vendrell JP
J Clin Virol; 2011 Sep; 52(1):33-7. PubMed ID: 21684200
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis.
Royston I; Sullivan JL; Periman PO; Perlin E
N Engl J Med; 1975 Dec; 293(23):1159-63. PubMed ID: 171568
[TBL] [Abstract][Full Text] [Related]
14. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
15. The MLC response of patients with infectious mononucleosis to Epstein-Barr virus-transformed cells.
Wasik M; Myc A; Matej H; Rudzka L
Arch Immunol Ther Exp (Warsz); 1983; 31(6):871-8. PubMed ID: 6331340
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.
Wingate PJ; McAulay KA; Anthony IC; Crawford DH
J Med Virol; 2009 May; 81(5):870-7. PubMed ID: 19319950
[TBL] [Abstract][Full Text] [Related]
17. Immune surveillance against Epstein-Barr virus.
Moss DJ; Burrows SR; Khanna R; Misko IS; Sculley TB
Semin Immunol; 1992 Apr; 4(2):97-104. PubMed ID: 1377517
[TBL] [Abstract][Full Text] [Related]
18. The effect of tinidazole on primary EBV infection and immunocompetence.
Marklund G; Ernberg I; Britton S; Lundberg C
Scand J Infect Dis; 1984; 16(1):17-23. PubMed ID: 6320359
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis.
Jondal M
Clin Exp Immunol; 1976 Jul; 25(1):1-5. PubMed ID: 186222
[TBL] [Abstract][Full Text] [Related]
20. T-cell control of herpesvirus infections: lessons from the Epstein-Barr virus.
Rickinson AB
Prog Brain Res; 1983; 59():189-202. PubMed ID: 6320264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
